# US 2004/0204387 A1 · Methods of preventing, treating and diagnosing disorders of protein aggregation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204387 A1
- Document ID: US20040204387A1
- Status: Published application
- Kind: A1
- Application number: 10/787,621
- Filed: 2004-02-26
- Published: 2004-10-14
- Earliest claimed: 2003-02-27
- Inventors: JoAnne McLaurin
- Web page: https://patentgrep.com/patent/US20040204387A1

## CPC

- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 51/04: Organic compounds
- A61K 51/0491: {Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- G01N 33/60: involving radioactive labelled substances
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof.

## Claims

### Claim 1

A method of treating or preventing in a subject a condition of the central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence comprising administering to said subject a pharmaceutically effective amount of a compound having the following structure:
6
wherein each of R1, R1′, R2, R2′, R3, R3′, R4, R4′, R5, R5′, R6, and R6′ is independently selected from the group of:
(a) hydrogen atom;
(b) NHR7, wherein said R7 is selected from the group of hydrogen; C2-C10 acyl and C1-C10 alkyl;
(c) NR8R9, wherein said R8 is C2-C10 acyl or C1-C10 alkyl and said R9 is C2-C10 acyl or C1-C10 alkyl;
(d) OR10, wherein said R10 is selected from the group of no group, hydrogen, C2-C10 acyl, C1-C10 alkyl and SO3H;
(e) C5-C7 glycosyl;
(f) C3-C8 cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OH, NH2, SH, OSO3H and OPO3H2;
(g) SR11, wherein R11 is selected from the group of hydrogen, C1-C10 alkyl and O3H;
(h) C1-C10 alkyl optionally substituted with a substituent selected from the group of hydrogen, OR10, NHR7, NR8R9 and SR11; and
(i) C3-C8 cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OR10, NHR7, NR8R9 and SR11 ,
providing that the compound is not myo-inositol.

### Claim 2 (depends on 1)

The method of claim 1, wherein said compound is said compound is a 1,2,3,4,5 ,6-cyclohexanehexol.

### Claim 3 (depends on 2)

The method of claim 2, wherein said compounds is selected from the group of cis-, epi-, allo-, muco-, neo-, scyllo-, D-chiro- and L-chiro-inositols.

### Claim 4 (depends on 1)

The method of claim 1, wherein said compound is a 1,2,3,4,5-cyclohexanepentol.

### Claim 5 (depends on 4)

The method of claim 4, wherein said compound is a quercitol selected from the group of epi-, vibo-, scyllo-, allo-, talo-, gala-, cis-, muco-, neo-, proto-quercitols and enantiomers thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein said compound is selected from the group of a cyclohexanetetrol, a cyclohexanetriol, stereoisomer of cyclohexanetetrol, stereoisimer of cyclohexanetriol, enantiomer of cyclohexanetetrol, and enantiomer of cyclohexanetriol.

### Claim 7 (depends on 1)

The method of claim 1, wherein said compound is a pentahydroxycyclohexanone or a stereoisomer or an enantoimer thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein said compound is an inosose selected from the group of scyllo-inosose, L-chiro-inosose-1 and L-epi-inosose.

### Claim 9 (depends on 1)

The method of claim 1, wherein said compound is a trihydroxycyclohexanone, or a stereoisomer or an enantiomer thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein said compound is (−)-1-deory-scyllo-inosose.

### Claim 11 (depends on 1)

The method of claim 1, wherein said compound is a pentahydroxycyclohexanone, or a stereoisomer or an enantiomer thereof

### Claim 12 (depends on 11)

The method of claim 11, wherein said compound is an inosose selected from the group of scyllo-inosose, L-chiro-inosose-1 and L-epi-inosose.

### Claim 13 (depends on 1)

The method of claim 1, wherein said compound is a trihydroxyxcyclohexanone or a stereoisomer or an enantiomer thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein said compound is (−)-1-deoxy-scyllo-inosose.

### Claim 15 (depends on 1)

The method of claim 1, wherein said compound is an 0-monomethyl-cyclohexanehexol or a stereoisomer or an enantiomer thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein said compound is selected from the group of D-pinitol, L-quebrachitol and D-bornesitol.

### Claim 17 (depends on 1)

The method of claim 1, wherein said compound is selected from the group of monoaminocyclohexanepentols (inosamines), diaminocyclohexanetetrols (inosadiamines), diaminocyclohexanetriols, stereoisomers thereof and enantiomers thereof, and pharmaceutically acceptable salts thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein said compound is selected from the group of L-neo-inosamine, DL-epi-inosamine-2, streptamine and deoxystreptamine.

### Claim 19 (depends on 1)

The method of claim 1, wherein said compound is a monomercapto-cyclohexanepentol or a stereoisomer or an enantiomer thereof

### Claim 20 (depends on 19)

The method of claim 19, wherein said compound is L-1-deoxy-1-mercapto-8-O-methyl-chiro-inositol.

### Claim 21 (depends on 1)

The method of claim 1, wherein said compound is scyllo-inositol.

### Claim 22 (depends on 1)

The method of claim 1, wherein said compound is allo-inositol.

### Claim 23 (depends on 1)

The method of claim 1, wherein said condition of the central or peripheral nervous system or systemic organ results in the deposition of proteins, protein fragments and peptides in beta-pleated sheats and/or fibrils and/or aggregates.

### Claim 24 (depends on 23)

The method of claim 23, wherein said condition of the central or peripheral nervous system or systemic organ is selected from the group of: Alzheimer's disease, presenile and senile forms; amyloid angiopathy; mild cognitive impairment; Alzheimer's disease-related dementia; tauopathy; a-synucleinopathy; Parkinson's disease; Amyotrophic Lateral Sclerosis; motor neuron Disease; Spastic paraplegia; Huntington's Disease, spinocerebellar ataxia, Freidrich's Ataxia; neurodegenerative diseases associated with intracellular and/or intraneuronal aggregates of proteins with polyglutamine, polyalanine or other repeats arising from pathological expansions of tri- or tetra-nucleotide elements within corresponding genes; cerebrovascular diseases; Down's syndrome; head trauma with post-traumatic accumulation of amyloid beta peptide; Prion related disease; Familial British Dementia; Familial Danish Dementia; Presenile Dementia with Spastic Ataxia; Cerebral Amyloid Angiopathy, British Type; Presenile Dementia With Spastic Ataxia Cerebral Amyloid Angiopathy, Danish Type; Familial encephalopathy with neuroserpin inclusion bodies (FENIB); Amyloid Polyneuropathy; Inclusion Body myositis due to amyloid beta peptide; Familial and Finnish Type Amyloidosis; Systemic amyloidosis associated with multiple myeloma; Familial Mediterranean Fever; chronic infections and inflammations; and Type II Diabetes Mellitus associate with islet amyloid polypeptide (IAPP).

### Claim 25 (depends on 24)

The method of claim 24, wherein said condition of the central or peripheral nervous system or systemic organ is Alzheimer's disease.

### Claim 26 (depends on 24)

The method of claim 24, wherein said Alzheimer's disease-related dementias is vascular or Alzheimer dementia.

### Claim 27 (depends on 24)

The method of claim 24, wherein said tauopathy is selected from the group of argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, diffuse neurofibrillary tangles with calcification, frontotemporal dementia with parkinsonism, Prion-related disease, Hallervorden-Spatz disease, myotonic dystrophy, Niemann-Pick disease type C, non-Guamanian Motor Neuron disease with neurofibrillary tangles, Pick's disease, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, and tangle only dementia.

### Claim 28 (depends on 24)

The method of claim 24, wherein said ac-synucleinopathy is selected from the group of dementia with Lewy bodies, multiple system atrophy with glial cytoplasmic inclusions, Shy-Drager syndrome, striatonigral degeneration, olivopontocerebellar atrophy, neurodegeneration with brain iron accumulation type I, olfactory dysfunction, and amyotrophic lateral sclerosis.

### Claim 29 (depends on 24)

The method of claim 24, wherein said condition of the central or peripheral nervous system or systemic organ is Parkinson's disease.

### Claim 30 (depends on 29)

The method of claim 29, wherein said Parkinson's disease is familial.

### Claim 31 (depends on 29)

The method of claim 29, wherein said Parkinson's disease is non-familial

### Claim 32 (depends on 24)

The method of claim 24, wherein said Motor Neuron Disease is associated with filaments and aggregates of neurofilament and/or superoxide dismutase proteins.

### Claim 33 (depends on 24)

The method of claim 24, wherein said Spastic paraplegia is associated with defective function of chaperones and/or triple A proteins.

### Claim 34 (depends on 24)

The method of claim 24, wherein said spinocerebellar ataxia is DRPLA or Machado-Joseph Disease.

### Claim 35 (depends on 24)

The method of claim 24, wherein said Prion related disease is selected from the group of Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker disease, and variant Creutzfeldt-Jakob disease.

### Claim 36 (depends on 34)

The method of claim 34, wherein said Amyloid Polyneuropathy is Senile amyloid polyneuropathy or Systemic Amyloidosis.

### Claim 37 (depends on 1)

The method of claim 1, wherein said compound is administered at a dose of about 1 mg to about 1 g per kg of the weight of said subject.

### Claim 38 (depends on 37)

The method of claim 37, wherein said compound is administered at a dose of about 1 mg to about 200 mg per kg of the weight of said subject.

### Claim 39 (depends on 37)

The method of claim 37, wherein said compound is administered at a dose of about 10 mg to about 100 mg per kg of the weight of said subject.

### Claim 40 (depends on 37)

The method of claim 37, wherein said compound is administered at a dose of about 30 mg to about 70 mg per kg of the weight of said subject.

### Claim 41

A method of preventing abnormal protein folding, abnormal protein aggregation, amyloid formation, deposition, accumulation, or persistence, or amyloid lipid interactions in a subject comprising administering to said subject a pharmaceutically effective amount of a compound having the following structure:
7
wherein each of R1, R1′, R2, R2′, R3, R3′, R4, R4′, R5, R5′, R6, and R6′ is independently selected from the group of:
(a) hydrogen atom;
(b) NHR7, wherein said R7 is selected from the group of hydrogen; C2-C10 acyl and C1-C10 alkyl;
(c) NR8R9, wherein said R8 is C2-C10 acyl or C1-C10 alkyl and said R9 is C2-C10 acyl or C1-C10 alkyl;
(d) OR10, wherein said R10 is selected from the group of no group, hydrogen, C2-C10 acyl, C1-C10 alkyl and SO3H;
(e) C5-C7 glycosyl;
(f) C3-C8 cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OH, NH2, SH, OSO3H and OPO3H2;
(g) SR11, wherein R11 is selected from the group of hydrogen, C1-C10 alkyl and O3H;
(h) C1-C10 alkyl optionally substituted with a substituent selected from the group of hydrogen, OR10, NHR7, NR8R9 and SR11; and
(i) C3-C8 cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OR10, NHR7, NR8R9 and SR11,
providing that the compound is not myo-inositol.

### Claim 42 (depends on 41)

The method of claim 41, wherein said compound is said compound is a 1,2,3,4,5,6-cyclohexanehexol.

### Claim 43 (depends on 42)

The method of claim 42, wherein said compounds is selected from the group of cis-, epi-, allo-, muco-, neo-, scyllo-, D-chiro- and L-chiro-inositols.

### Claim 44 (depends on 41)

The method of claim 41, wherein said compound is a 1,2,3,4,5-cyclohexanepentol.

### Claim 45 (depends on 44)

The method of claim 44, wherein said compound is a quercitol selected from the group of epi-, vibo-, scyllo-, allo-, talo-, gala-, cis-, muco-, neo-, proto-quercitols and enantiomers thereof.

### Claim 46 (depends on 41)

The method of claim 41, wherein said compound is selected from the group of a cyclohexanetetrol, a cyclohexanetriol, stereoisomer of cyclohexanetetrol, stereoisimer of cyclohexanetriol, enantiomer of cyclohexanetetrol, and enantiomer of cyclohexanetriol.

### Claim 47 (depends on 41)

The method of claim 41, wherein said compound is a pentahydroxycyclohexanone or a stereoisomer or an enantoimer thereof.

### Claim 48 (depends on 47)

The method of claim 47, wherein said compound is an inosose selected from the group of scyllo-inosose, L-chiro-inosose-1 and L-epi-inosose.

### Claim 49 (depends on 41)

The method of claim 41, wherein said compound is a trihydroxycyclohexanone, or a stereoisomer or an enantiomer thereof.

### Claim 50 (depends on 49)

The method of claim 49, wherein said compound is (−)-1-deoxy-scyllo-inosose.

### Claim 51 (depends on 41)

The method of claim 41, wherein said compound is a pentahydroxycyclohexanone, or a stereoisomer or an enantiomer thereof.

### Claim 52 (depends on 51)

The method of claim 51, wherein said compound is an inosose selected from the group of scyllo-inosose, L-chiro-inosose-1 and L-epi-inosose.

### Claim 53 (depends on 41)

The method of claim 41, wherein said compound is a trihydroxyxcyclohexanone or a stereoisomer or an enantiomer thereof.

### Claim 54 (depends on 53)

The method of claim 53, wherein said compound is (−)-1-deoxy-scyllo-inosose.

### Claim 55 (depends on 41)

The method of claim 41, wherein said compound is an 0-monomethyl-cyclohexanehexol or a stereoisomer or an enantiomer thereof.

### Claim 56 (depends on 55)

The method of claim 55, wherein said compound is selected from the group of D-pinitol, L-quebrachitol and D-bomesitol.

### Claim 57 (depends on 41)

The method of claim 41, wherein said compound is selected from the group of monoaminocyclohexanepentols (inosamines), diaminocyclohexanetetrols (inosadiamines), diaminocyclohexanetriols, tstereoisomers thereof and, enantiomers thereof, and pharmaceutically acceptable salts thereof.

### Claim 58 (depends on 57)

The method of claim 57, wherein said compound is selected from the group of L-neo-inosamine, DL-epi-inosamine-2, streptamine and deoxystreptamine.

### Claim 59 (depends on 41)

The method of claim 41, wherein said compound is a monomercapto-cyclohexanepentol or a stereoisomer or an enantiomer thereof

### Claim 60 (depends on 59)

The method of claim 59, wherein said compound is 1L-1-deoxy-1-mercapto-8-O-methyl-chiro-inositol.

### Claim 61 (depends on 41)

The method of claim 41, wherein said compound is scyllo-inositol.

### Claim 62 (depends on 41)

The method of claim 41, wherein said compound is allo-inositol.

### Claim 63 (depends on 41)

The method of claim 41, wherein said condition of the central or peripheral nervous system or systemic organ results in the deposition of proteins, protein fragments and peptides in beta-pleated sheats and/or fibrils and/or aggregates.

### Claim 64 (depends on 63)

The method of claim 63, wherein said condition of the central or peripheral nervous system or systemic organ is selected from the group of: Alzheimer's disease, presenile and senile forms; amyloid angiopathy; mild cognitive impairment; Alzheimer's disease-related dementia; tauopathy; α-synucleinopathy; Parkinson's disease; Amyotrophic Lateral Sclerosis; motor neuron Disease; Spastic paraplagia; Huntington's Disease, spinocerebellar ataxia, Freidrich's Ataxia; neurodegenerative diseases associated with intracellular and/or intraneuronal aggregates of proteins with polyglutamine, polyalanine or other repeats arising from pathological expansions of tri- or tetra-nucleotide elements within corresponding genes; cerebrovascular diseases; Down's syndrome; head trauma with post-traumatic accumulation of amyloid beta peptide; Prion related disease; Familial British Dementia; Familial Danish Dementia; Presenile Dementia with Spastic Ataxia; Cerebral Amyloid Angiopathy, British Type; Presenile Dementia With Spastic Ataxia Cerebral Amyloid Angiopathy, Danish Type; Familial encephalopathy with neuroserpin inclusion bodies (FENIB); Amyloid Polyneuropathy; Inclusion Body myositis due to amyloid beta peptide; Familial and Finnish Type Amyloidosis; Systemic amyloidosis associated with multiple myeloma; Familial Mediterranean Fever; chronic infections and inflammations; and Type II Diabetes Mellitus associate with islet amyloid polypeptide (IAPP).

### Claim 65 (depends on 64)

The method of claim 64, wherein said condition of the central or peripheral nervous system or systemic organ is Alzheimer's disease.

### Claim 66 (depends on 64)

The method of claim 64, wherein said Alzheimer's disease-related dementias is vascular or Alzheimer dementia.

### Claim 67 (depends on 64)

The method of claim 64, wherein said tauopathy is selected from the group of argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, diffuse neurofibrillary tangles with calcification, frontotemporal dementia with parkinsonism, Prion-related disease, Hallervorden-Spatz disease, myotonic dystrophy, Niemann-Pick disease type C, non-Guamanian Motor Neuron disease with neurofibrillary tangles, Pick's disease, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, and tangle only dementia.

### Claim 68 (depends on 64)

The method of claim 64, wherein said α-synucleinopathy is selected from the group of dementia with Lewy bodies, multiple system atrophy with glial cytoplasmic inclusions, Shy-Drager syndrome, striatonigral degeneration, olivopontocerebellar atrophy, neurodegeneration with brain iron accumulation type I, olfactory dysfunction, and amyotrophic lateral sclerosis.

### Claim 69 (depends on 24)

The method of claim 24, wherein said condition of the central or peripheral nervous system or systemic organ is Parkinson's disease.

### Claim 70 (depends on 69)

The method of claim 69, wherein said Parkinson's disease is familial.

### Claim 71 (depends on 69)

The method of claim 69, wherein said Parkinson's disease is non-familial

### Claim 72 (depends on 64)

The method of claim 64, wherein said Motor Neuron Disease is associated with filaments and aggregates of neurofilament and/or superoxide dismutase proteins.

### Claim 73 (depends on 64)

The method of claim 64, wherein said Spastic paraplagia is associated with defective function of chaperones and/or triple A proteins.

### Claim 74 (depends on 64)

The method of claim 64, wherein said spinocerebellar ataxia is DRPLA or Machado-Joseph Disease.

### Claim 75 (depends on 64)

The method of claim 64, wherein said Prion related disease is selected from the group of Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, and variant Creutzfeldt-Jakob disease.

### Claim 76 (depends on 64)

The method of claim 64, wherein said Amyloid Polyneuropathy is Senile amyloid polyneuropathy or Systemic Amyloidosis.

### Claim 77 (depends on 41)

The method of claim 41, wherein said compound is administered at a dose of about 1 mg to about 1 g per kg of the weight of said subject.

### Claim 78 (depends on 77)

The method of claim 77, wherein said compound is administered at a dose of about 1 mg to about 200 mg per kg of the weight of said subject.

### Claim 79 (depends on 77)

The method of claim 77, wherein said compound is administered at a dose of about 10 mg to about 100 mg per kg of the weight of said subject.

### Claim 80 (depends on 77)

The method of claim 77, wherein said compound is administered at a dose of about 30 mg to about 70 mg per kg of the weight of said subject.

### Claim 81

A method of causing the dissociation of abnormally aggregated proteins and/or dissolving or disrupting pre-formed or pre-deposited amyloid fibril or amyloid in a subject comprising administering to said subject a pharmaceutically effective amount of a compound having the following structure:
8
wherein each of R1, R1′, R2, R2′, R3, R3′, R4, R4′, R5, R5′, R6, and R6′ is
independently selected from the group of:
(a) hydrogen atom;
(b) NHR7, wherein said R7 is selected from the group of hydrogen; C2-C10 acyl and C1-C10 alkyl;
(c) NR8R9, wherein said R8 is C2-C10 acyl or C1-C10 alkyl and said R9 is C2-C10 acyl or C1-C10 alkyl;
(d) OR10, wherein said R10 is selected from the group of no group, hydrogen, C2-C10 acyl, C1-C10 alkyl and SO3H;
(e) C5-C7 glycosyl;
(f) C3-C8 cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OH, NH2, SH, OSO3H and OPO3H2;
(g) SR11, wherein R11 is selected from the group of hydrogen, C1-C10 alkyl and O3H;
(h) C1-C10 alkyl optionally substituted with a substituent selected from the group of hydrogen, OR10, NHR7, NR8R9 and SR11; and
(i) C3-C8 cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OR10, NHR7, NR8R9 and SR11, providing that the compound is not myo-inositol.

### Claim 82 (depends on 81)

The method of claim 81, wherein said compound is said compound is a 1,2,3,4,5,6-cyclohexanehexol.

### Claim 83 (depends on 82)

The method of claim 82, wherein said compounds is selected from the group of cis-, epi-, allo-, muco-, neo-, scyllo-, D-chiro- and L-chiro-inositols.

### Claim 84 (depends on 81)

The method of claim 81, wherein said compound is a 1,2,3,4,5-cyclohexanepentol.

### Claim 85 (depends on 84)

The method of claim 84, wherein said compound is a quercitol selected from the group of epi-, vibo-, scyllo-, allo-, talo-, gala-, cis-, muco-, neo-, proto-quercitols and enantiomers thereof.

### Claim 86 (depends on 81)

The method of claim 81, wherein said compound is selected from the group of a cyclohexanetetrol, a cyclohexanetriol, stereoisomer of cyclohexanetetrol, stereoisimer of cyclohexanetriol, enantiomer of cyclohexanetetrol, and enantiomer of cyclohexanetriol.

### Claim 87 (depends on 81)

The method of claim 81, wherein said compound is a pentahydroxycyclohexanone or a stereoisomer or an enantoimer thereof.

### Claim 88 (depends on 87)

The method of claim 87, wherein said compound is an inosose selected from the group of scyllo-inosose, L-chiro-inosose-I and L-epi-inosose.

### Claim 89 (depends on 81)

The method of claim 81, wherein said compound is a trihydroxycyclohexanone, or a stereoisomer or an enantiomer thereof.

### Claim 90 (depends on 89)

The method of claim 89, wherein said compound is (−)-1-deoxy-scyllo-inosose.

### Claim 91 (depends on 81)

The method of claim 81, wherein said compound is a pentahydroxycyclohexanone, or a stereoisomer or an enantiomer thereof.

### Claim 92 (depends on 91)

The method of claim 91, wherein said compound is an inosose selected from the group of scyllo-inosose, L-chiro-inosose-I and L-epi-inosose.

### Claim 93 (depends on 81)

The method of claim 81, wherein said compound is a trihydroxyxcyclohexanone or a stereoisomer or an enantiomer thereof.

### Claim 94 (depends on 93)

The method of claim 93, wherein said compound is (−)-1-deoxy-scyllo-inosose.

### Claim 95 (depends on 81)

The method of claim 81, wherein said compound is an O-monomethyl-cyclohexanehexol or a stereoisomer or an enantiomer thereof.

### Claim 96 (depends on 95)

The method of claim 95, wherein said compound is selected from the group of D-pinitol, L-quebrachitol and D-bomesitol.

### Claim 97 (depends on 81)

The method of claim 81, wherein said compound is selected from the group of monoaminocyclohexanepentols (inosamines), diaminocyclohexanetetrols (inosadiamines), diaminocyclohexanetriols, tstereoisomers thereof and, enantiomers thereof, and pharmaceutically acceptable salts thereof.

### Claim 98 (depends on 97)

The method of claim 97, wherein said compound is selected from the group of L-neo-inosamine, DL-epi-inosamine-2, streptamine and deoxystreptamine.

### Claim 99 (depends on 81)

The method of claim 81, wherein said compound is a monomercapto-cyclohexanepentol or a stereoisomer or an enantiomer thereof.

### Claim 100 (depends on 99)

The method of claim 99, wherein said compound is 1L-1-deoxy-1-mercapto-8-O-methyl-chiro-inositol.

### Claim 101 (depends on 91)

The method of claim 91, wherein said compound is scyllo-inositol.

### Claim 102 (depends on 81)

The method of claim 81, wherein said compound is allo-inositol.

### Claim 103 (depends on 81)

The method of claim 81, wherein said condition of the central or peripheral nervous system or systemic organ results in the deposition of proteins, protein fragments and peptides in beta-pleated sheats and/or fibrils and/or aggregates.

### Claim 104 (depends on 103)

The method of claim 103, wherein said condition of the central or peripheral nervous system or systemic organ is selected from the group of: Alzheimer's (ii disease, presenile and senile forms; amyloid angiopathy; mild cognitive impairment; Alzheimer's disease-related dementia; tauopathy; α-synucleinopathy; Parkinson's disease; Amyotrophic Lateral Sclerosis; motor neuron Disease; Spastic paraplagia; Huntington's Disease, spinocerebellar ataxia, Freidrich's Ataxia; neurodegenerative diseases associated with intracellular and/or intraneuronal aggregates of proteins with polyglutamine, polyalanine or other repeats arising from pathological expansions of tri- or tetra-nucleotide elements within corresponding genes; cerebrovascular diseases; Down's syndrome; head trauma with post-traumatic accumulation of amyloid beta peptide; Prion related disease; Familial British Dementia; Familial Danish Dementia; Presenile Dementia with Spastic Ataxia; Cerebral Amyloid Angiopathy, British Type; Presenile Dementia With Spastic Ataxia Cerebral Amyloid Angiopathy, Danish Type; Familial encephalopathy with neuroserpin inclusion bodies (FENIB); Amyloid Polyneuropathy; Inclusion Body myositis due to amyloid beta peptide; Familial and Finnish Type Amyloidosis; Systemic amyloidosis associated with multiple myeloma; Familial Mediterranean Fever; chronic infections and inflammations; and Type II Diabetes Mellitus associate with islet amyloid polypeptide (IAPP).

### Claim 105 (depends on 104)

The method of claim 104, wherein said condition of the central or peripheral nervous system or systemic organ is Alzheimer's disease.

### Claim 106 (depends on 104)

The method of claim 104, wherein said Alzheimer's disease-related dementias is vascular or Alzheimer dementia.

### Claim 107 (depends on 104)

The method of claim 104, wherein said tauopathy is selected from the group of argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, diffuse neurofibrillary tangles with calcification, frontotemporal dementia with parkinsonism, Prion-related disease, Hallervorden-Spatz disease, myotonic dystrophy, Niemann-Pick disease type C, non-Guamanian Motor Neuron disease with neurofibrillary tangles, Pick's disease, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, and tangle only dementia.

### Claim 108 (depends on 104)

The method of claim 104, wherein said ac-synucleinopathy is selected from the group of dementia with Lewy bodies, multiple system atrophy with glial cytoplasmic inclusions, Shy-Drager syndrome, striatonigral degeneration, olivopontocerebellar atrophy, neurodegeneration with brain iron accumulation type I, olfactory dysfunction, and amyotrophic lateral sclerosis.

### Claim 109 (depends on 84)

The method of claim 84, wherein said condition of the central or peripheral nervous system or systemic organ is Parkinson's disease.

### Claim 110 (depends on 109)

The method of claim 109, wherein said Parkinson's disease is familial.

### Claim 111 (depends on 109)

The method of claim 109, wherein said Parkinson's disease is non-familial

### Claim 112 (depends on 104)

The method of claim 104, wherein said Motor Neuron Disease is associated with filaments and aggregates of neurofilament and/or superoxide dismutase proteins.

### Claim 113 (depends on 104)

The method of claim 104, wherein said Spastic paraplagia is associated with defective function of chaperones and/or triple A proteins.

### Claim 114 (depends on 104)

The method of claim 104, wherein said spinocerebellar ataxia is DRPLA or Machado-Joseph Disease.

### Claim 115 (depends on 104)

The method of claim 104, wherein said Prion related disease is selected from the group of Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker disease, 0 and variant Creutzfeldt-Jakob disease.

### Claim 116 (depends on 104)

The method of claim 104, wherein said Amyloid Polyneuropathy is Senile amyloid polyneuropathy or Systemic Amyloidosis.

### Claim 117 (depends on 81)

The method of claim 81, wherein said compound is administered at a dose of about 1 mg to about 1 g per kg of the weight of said subject.

### Claim 118 (depends on 117)

The method of claim 117, wherein said compound is administered at a dose of about 1 mg to about 200 mg per kg of the weight of said subject.

### Claim 119 (depends on 117)

The method of claim 117, wherein said compound is administered at a dose of about 10 mg to about 100 mg per kg of the weight of said subject.

### Claim 120 (depends on 117)

The method of claim 117, wherein said compound is administered at a dose of about 30 mg to about 70 mg per kg of the weight of said subject.

### Claim 121

A method of diagnosing the presence of abnormally folded or aggregated protein and/or amyloid fibril or amyloid in a subject comprising:
(a) administering to said subject a radioactive compound or compound tagged with a substance that emits a detectable signal in a quantity sufficient and under conditions to allow for the binding of said compound to the abnormally folded or aggregated protein and/or fibrils or amyloid, if present; and
(b) detecting the radioactivity or the signal from the compound bound to the abnormally folded or aggregated protein and/or fibrils or amyloid, thus diagnosing the presence of abnormally folded or aggregated protein and/or amyloid fibril or amyloid in said subject, wherein said compound has the following structure:
9
wherein each of R1, R1′, R2, R2′, R3, R3′, R4, R4′, R5, R5′, R6, and R6′ is independently selected from the group of:
(a) hydrogen atom;
(b) NHR7, wherein said R7 is selected from the group of hydrogen; C2-C10 acyl and C1-C10 alkyl;
(c) NR8R9, wherein said R8 is C2-C1 0 acyl or C1-C10 alkyl and said R9 is C2-C10 acyl or C1-C10 alkyl;
(d) OR10, wherein said R10 is selected from the group of no group, hydrogen, C2-C10 acyl, C1-C10 alkyl and SO3H;
(e) C5-C7 glycosyl;
(f) C3-C8 cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OH, NH2, SH, OSO3H and OPO3H2;
(g) SR11, wherein R11 is selected from the group of hydrogen, C1-C10 alkyl and O3H;
(h) C1-C10 alkyl optionally substituted with a substituent selected from the group of hydrogen, OR10, NHR7, NR8R9 and SR11; and
(i) C3-C8 cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OR10, NHR7, NR8R9 and SR11,
providing that the compound is not myo-inositol.

### Claim 122 (depends on 121)

The method of claim 121, wherein said compound is said compound is a 1,2,3,4,5,6-cyclohexanehexol.

### Claim 123 (depends on 122)

The method of claim 122, wherein said compounds is selected from the group of cis-, epi-, allo-, muco-, neo-, scyllo-, D-chiro- and L-chiro-inositols.

### Claim 124 (depends on 121)

The method of claim 121, wherein said compound is a 1,2,3,4,5-cyclohexanepentol.

### Claim 125 (depends on 124)

The method of claim 124, wherein said compound is quercitol selected from the group of epi-, vibo-, scyllo-, allo-, talo-, gala-, cis-, muco-, neo-, proto-quercitols and enantiomers thereof.

### Claim 126 (depends on 121)

The method of claim 121, wherein said compound is selected from the group of a cyclohexanetetrol, a cyclohexanetriol, stereoisomer of cyclohexanetetrol, stereoisimer of cyclohexanetriol, enantiomer of cyclohexanetetrol, and enantiomer of cyclohexanetriol.

### Claim 127 (depends on 121)

The method of claim 121, wherein said compound is a pentahydroxycyclohexanone or a stereoisomer or an enantoimer thereof.

### Claim 128 (depends on 127)

The method of claim 127, wherein said compound is an inosose selected from the group of scyllo-inosose, L-chiro-inosose-1 and L-epi-inosose.

### Claim 129 (depends on 121)

The method of claim 121, wherein said compound is a trihydroxyxcyclohexanone, or a stereoisomer or an enantiomer thereof.

### Claim 130 (depends on 129)

The method of claim 129, wherein said compound is (−)-1-deoxy-scyllo-inosose.

### Claim 131 (depends on 121)

The method of claim 121, wherein said compound is a pentahydroxycyclohexanone, or a stereoisomer or an enantiomer thereof.

### Claim 132 (depends on 131)

The method of claim 131, wherein said compound is an inosose selected from the group of scyllo-inosose, L-chiro-inosose-1 and L-epi-inosose.

### Claim 133 (depends on 121)

The method of claim 121, wherein said compound is a trihydroxyxcyclohexanone or a stereoisomer or an enantiomer thereof.

### Claim 134 (depends on 133)

The method of claim 133, wherein said compound is (−)-1-deoxy-scyllo-inosose.

### Claim 135 (depends on 121)

The method of claim 121, wherein said compound is an O-monomethyl-cyclohexanehexol or a stereoisomer or an enantiomer thereof.

### Claim 136 (depends on 135)

The method of claim 135, wherein said compound is selected from the 0 group of D-pinitol, L-quebrachitol and D-bomesitol.

### Claim 137 (depends on 121)

The method of claim 121, wherein said compound is selected from the group of monoaminocyclohexanepentols (inosamines), diaminocyclohexanetetrols (inosadiamines), diaminocyclohexanetriols, tstereoisomers thereof and, enantiomers thereof, and pharmaceutically acceptable salts thereof.

### Claim 138 (depends on 137)

The method of claim 137, wherein said compound is selected from the group of L-neo-inosamine, DL-epi-inosamine-2, streptamine and deoxystreptamine.

### Claim 139 (depends on 121)

The method of claim 121, wherein said compound is a monomercapto-cyclohexanepentol or a stereoisomer or an enantiomer thereof

### Claim 140 (depends on 139)

The method of claim 139, wherein said compound is 1L-1-deoxy-1-mercapto-8-O-methyl-chiro-inositol.

### Claim 141 (depends on 121)

The method of claim 121, wherein said compound is scyllo-inositol.

### Claim 142 (depends on 121)

The method of claim 121, wherein said compound is allo-inositol.

### Claim 143 (depends on 121)

The method of claim 121, wherein said condition of the central or peripheral nervous system or systemic organ results in the deposition of proteins, protein fragments and peptides in beta-pleated sheats and/or fibrils and/or aggregates.

### Claim 144 (depends on 143)

The method of claim 143, wherein said condition of the central or peripheral nervous system or systemic organ is selected from the group of: Alzheimer's disease, presenile and senile forms; amyloid angiopathy; mild cognitive impairment; Alzheimer's disease-related dementia; tauopathy; α-synucleinopathy; Parkinson's disease; Amyotrophic Lateral Sclerosis; motor neuron Disease; Spastic paraplagia; Huntington's Disease, spinocerebellar ataxia, Freidrich's Ataxia; neurodegenerative diseases associated with intracellular and/or intraneuronal aggregates of proteins with polyglutamine, polyalanine or other repeats arising from pathological expansions of tri- or tetra-nucleotide elements within corresponding genes; cerebrovascular diseases; Down's syndrome; head trauma with post-traumatic accumulation of amyloid beta peptide; Prion related disease; Familial British Dementia; Familial Danish Dementia; Presenile Dementia with Spastic Ataxia; Cerebral Amyloid Angiopathy, British Type; Presenile Dementia With Spastic Ataxia Cerebral Amyloid Angiopathy, Danish Type; Familial encephalopathy with neuroserpin inclusion bodies (FENIB); Amyloid Polyneuropathy; Inclusion Body myositis due to amyloid beta peptide; Familial and Finnish Type Amyloidosis; Systemic amyloidosis associated with multiple myeloma; Familial Mediterranean Fever; chronic infections and inflammations; and Type II Diabetes Mellitus associate with islet amyloid polypeptide (IAPP).

### Claim 145 (depends on 144)

The method of claim 144, wherein said condition of the central or peripheral nervous system or systemic organ is Alzheimer's disease.

### Claim 146 (depends on 144)

The method of claim 144, wherein said Alzheimer's disease-related dementias is vascular or Alzheimer dementia.

### Claim 147 (depends on 144)

The method of claim 144, wherein said tauopathy is selected from the group of argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, diffuse neurofibrillary tangles with calcification, frontotemporal dementia with parkinsonism, Prion-related disease, Hallervorden-Spatz disease, myotonic dystrophy, Niemann-Pick disease type C, non-Guamanian Motor Neuron disease with neurofibrillary tangles, Pick's disease, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, and tangle only dementia.

### Claim 148 (depends on 144)

The method of claim 144, wherein said α-synucleinopathy is selected from the group of dementia with Lewy bodies, multiple system atrophy with glial cytoplasmic inclusions, Shy-Drager syndrome, striatonigral degeneration, olivopontocerebellar atrophy, neurodegeneration with brain iron accumulation type I , olfactory dysfunction, and amyotrophic lateral sclerosis.

### Claim 149 (depends on 144)

The method of claim 144, wherein said condition of the central or peripheral nervous system or systemic organ is Parkinson's disease.

### Claim 150 (depends on 149)

The method of claim 149, wherein said Parkinson's disease is familial.

### Claim 151 (depends on 149)

The method of claim 149, wherein said Parkinson's disease is non-familial

### Claim 152 (depends on 144)

The method of claim 144, wherein said Motor Neuron Disease is associated with filaments and aggregates of neurofilament and/or superoxide dismutase proteins.

### Claim 153 (depends on 144)

The method of claim 144, wherein said Spastic paraplagia is associated with defective function of chaperones and/or triple A proteins.

### Claim 154 (depends on 144)

The method of claim 144, wherein said spinocerebellar ataxia is DRPLA or Machado-Joseph Disease.

### Claim 155 (depends on 144)

The method of claim 144, wherein said Prion related disease is selected from the group of Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, and variant Creutzfeldt-Jakob disease.

### Claim 156 (depends on 144)

The method of claim 144, wherein said Amyloid Polyneuropathy is Senile amyloid polyneuropathy or Systemic Amyloidosis.

### Claim 157 (depends on 121)

The method of claim 121, wherein said compound is administered at a dose of about 1 mg to about 1 g per kg of the weight of said subject.

### Claim 158 (depends on 157)

The method of claim 157, wherein said compound is administered at a dose of about 1 mg to about 200 mg per kg of the weight of said subject.

### Claim 159 (depends on 121)

The method of claim 121, wherein said detectable signal is a fluorescent signal.

### Claim 160 (depends on 121)

The method of claim 121, wherein said detectable signal is a radioactive signal.

### Claim 161

A method of diagnosing the presence of abnormally folded or aggregated protein and/or amyloid fibril or amyloid in a subject comprising:
(a) collecting a sample from said subject;
(b) contacting said sample with a radioactive compound or compound tagged with a substance that emits a detectable signal under conditions to allow the binding of said compound to the abnormally folded or aggregated protein and/or amyloid fibril or amyloid if present; and
(c) detecting the radioactivity or the signal from the compound bound to the abnormally folded or aggregated protein and/or fibrils or amyloid, thus diagnosing the presence of abnormally folded or aggregated protein and/or amyloid fibril or amyloid in said subject, wherein said compound has the following structure:
10
wherein each of R1, R1′, R2, R2′, R3, R3′, R4, R4′, R5, R5′, R6, and R6′ is independently selected from the group of:
(a) hydrogen atom;
(b) NHR7, wherein said R7 is selected from the group of hydrogen; C2-C10 acyl and C1-C10 alkyl;
(c) NR8R9, wherein said R8 is C2-C10 acyl or C1-C10 alkyl and said R9 is C2-C10 acyl or C1-C10 alkyl;
(d) OR10, wherein said R10 is selected from the group of no group, hydrogen, C2-C10 acyl, C1-C10 alkyl and SO3H;
(e) C5-C7 glycosyl;
(f) C3-C8 cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OH, NH2, SH, OSO3H and OPO3H2;
(g) SR11, wherein R11 is selected from the group of hydrogen, C1-C10 alkyl and O3H;
(h) C1-C10 alkyl optionally substituted with a substituent selected from the group of hydrogen, OR10, NHR7, NR8R9 and SR11; and
(i) C3-C8 cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OR10, NHR7, NR8R9 and SR11,
providing that the compound is not myo-inositol.

### Claim 162 (depends on 161)

The method of claim 161, wherein said compound is said compound is a 1,2,3,4,5,6-cyclohexanehexol.

### Claim 163 (depends on 162)

The method of claim 162, wherein said compounds is selected from the group of cis-, epi-, allo-, muco-, neo-, scyllo-, D-chiro- and L-chiro-inositols.

### Claim 164 (depends on 161)

The method of claim 161, wherein said compound is a 1,2,3,4,5-cyclohexanepentol.

### Claim 165 (depends on 164)

The method of claim 164, wherein said compound is a quercitol selected from the group of epi-, vibo-, scyllo-, allo-, talo-, gala-, cis-, muco-, neo-, proto-quercitols and enantiomers thereof.

### Claim 166 (depends on 161)

The method of claim 161, wherein said compound is selected from the group of a cyclohexanetetrol, a cyclohexanetriol, stereoisomer of cyclohexanetetrol, stereoisimer of cyclohexanetriol, enantiomer of cyclohexanetetrol, and enantiomer of cyclohexanetriol.

### Claim 167 (depends on 161)

The method of claim 161, wherein said compound is a pentahydxycyclohexanone, a stereoisomer or an enantoimer thereof.

### Claim 168 (depends on 167)

The method of claim 167, wherein said compound is an inosose selected from the group of scyllo-inosose, L-chiro-inosose-I and L-epi-inosose.

### Claim 169 (depends on 161)

The method of claim 161, wherein said compound is a trihydroxyxcyclohexanone, or a stereoisomer or an enantiomer thereof.

### Claim 170 (depends on 169)

The method of claim 169, wherein said compound is (−)-1-deoxy-scyllo-inosose.

### Claim 171 (depends on 161)

The method of claim 161, wherein said compound is a pentahydroxycyclohexanone, or a stereoisomer or an enantiomer thereof.

### Claim 172 (depends on 171)

The method of claim 171, wherein said compound is an inosose selected from the group of scyllo-inosose, L-chiro-inosose-I and L-epi-inosose.

### Claim 173 (depends on 161)

The method of claim 161, wherein said compound is a trihydroxyxcyclohexanone or a stereoisomer or an enantiomer thereof.

### Claim 174 (depends on 163)

The method of claim 163, wherein said compound is (−)-1-deoxy-scyllo-inosose.

### Claim 175 (depends on 161)

The method of claim 161, wherein said compound is an O-monomethyl-cyclohexanehexol or a stereoisomer or an enantiomer thereof.

### Claim 176 (depends on 175)

The method of claim 175, wherein said compound is selected from the group of D-pinitol, L-quebrachitol and D-bomesitol.

### Claim 177 (depends on 161)

The method of claim 161, wherein said compound is selected from the group of monoaminocyclohexanepentols (inosamines), diaminocyclohexanetetrols (inosadiamines), diaminocyclohexanetriols, tstereoisomers thereof and, enantiomers thereof, and pharmaceutically acceptable salts thereof.

### Claim 178 (depends on 177)

The method of claim 177, wherein said compound is selected from the group of L-neo-inosamine, DL-epi-inosamine-2, streptamine and deoxystreptamine.

### Claim 179 (depends on 161)

The method of claim 161, wherein said compound is a monomercapto-cyclohexanepentol or a stereoisomer or an enantiomer thereof

### Claim 180 (depends on 179)

The method of claim 179, wherein said compound is 1L-1-deoxy-1-mercapto-8-O-methyl-chiro-inositol.

### Claim 181 (depends on 161)

The method of claim 161, wherein said compound is scyllo-inositol.

### Claim 182 (depends on 161)

The method of claim 161, wherein said compound is allo-inositol.

### Claim 183 (depends on 161)

The method of claim 161, wherein said condition of the central or peripheral nervous system or systemic organ results in the deposition of proteins, protein fragments and peptides in beta-pleated sheats and/or fibrils and/or aggregates.

### Claim 184 (depends on 183)

The method of claim 183, wherein said condition of the central or peripheral nervous system or systemic organ is selected from the group of: Alzheimer's disease, presenile and senile forms; amyloid angiopathy; mild cognitive impairment; Alzheimer's disease-related dementia; tauopathy; α-synucleinopathy; Parkinson's disease; Amyotrophic Lateral Sclerosis; motor neuron Disease; Spastic paraplagia; Huntington's Disease, spinocerebellar ataxia, Freidrich's Ataxia; neurodegenerative diseases associated with intracellular and/or intraneuronal aggregates of proteins with polyglutamine, polyalanine or other repeats arising from pathological expansions of tri- or tetra-nucleotide elements within corresponding genes; cerebrovascular diseases; Down's syndrome; head trauma with post-traumatic accumulation of amyloid beta peptide; Prion related disease; Familial British Dementia; Familial Danish Dementia; Presenile Dementia with Spastic Ataxia; Cerebral Amyloid Angiopathy, British Type; Presenile Dementia With Spastic Ataxia Cerebral Amyloid Angiopathy, Danish Type; Familial encephalopathy with neuroserpin inclusion bodies (FENIB); Amyloid Polyneuropathy; Inclusion Body myositis due to amyloid beta peptide; Familial and Finnish Type Amyloidosis; Systemic amyloidosis associated with multiple myeloma; Familial Mediterranean Fever; chronic infections and inflammations; and Type II Diabetes Mellitus associate with islet amyloid polypeptide (IAPP).

### Claim 185 (depends on 184)

The method of claim 184, wherein said condition of the central or peripheral nervous system or systemic organ is Alzheimer's disease.

### Claim 186 (depends on 184)

The method of claim 184, wherein said Alzheimer's disease-related dementias is vascular or Alzheimer dementia.

### Claim 187 (depends on 184)

The method of claim 184, wherein said tauopathy is selected from the group of argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, diffuse neurofibrillary tangles with calcification, frontotemporal dementia with parkinsonism, Prion-related disease, Hallervorden-Spatz disease, myotonic dystrophy, Niemann-Pick disease type C, non-Guamanian Motor Neuron disease with neurofibrillary tangles, Pick's disease, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, and tangle only dementia.

### Claim 188 (depends on 184)

The method of claim 184, wherein said a-synucleinopathy is selected from the group of dementia with Lewy bodies, multiple system atrophy with glial cytoplasmic inclusions, Shy-Drager syndrome, striatonigral degeneration, olivopontocerebellar atrophy, neurodegeneration with brain iron accumulation type I, olfactory dysfunction, and amyotrophic lateral sclerosis.

### Claim 189 (depends on 184)

The method of claim 184, wherein said condition of the central or peripheral nervous system or systemic organ is Parkinson's disease.

### Claim 190 (depends on 189)

The method of claim 189, wherein said Parkinson's disease is familial.

### Claim 191 (depends on 189)

The method of claim 189, wherein said Parkinson's disease is non-familial

### Claim 192 (depends on 184)

The method of claim 184, wherein said Motor Neuron Disease is associated with filaments and aggregates of neurofilament and/or superoxide dismutase proteins.

### Claim 193 (depends on 184)

The method of claim 184, wherein said Spastic paraplagia is associated with defective function of chaperones and/or triple A proteins.

### Claim 194 (depends on 184)

The method of claim 184, wherein said spinocerebellar ataxia is DRPLA or Machado-Joseph Disease.

### Claim 195 (depends on 184)

The method of claim 184, wherein said Prion related disease is selected from the group of Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, and variant Creutzfeldt-Jakob disease.

### Claim 196 (depends on 184)

The method of claim 184, wherein said Amyloid Polyneuropathy is Senile amyloid polyneuropathy or Systemic Amyloidosis.

### Claim 197 (depends on 161)

The method of claim 161, wherein said detectable signal is a fluorescent signal.

### Claim 198 (depends on 161)

The method of claim 161, wherein said detectable signal is a radioactive signal.

### Claim 199 (depends on 161)

The method of claim 161, wherein said detectable signal is an enzyme-linked immunosorbent assay signal

### Claim 200 (depends on 161)

The method of claim 161, wherein said sample is whole blood.

### Claim 201 (depends on 161)

The method of claim 161, wherein said sample is plasma.
